Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;59(2):253-256.
doi: 10.1111/ijd.14573. Epub 2019 Jul 8.

Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records

Candice Wang  1 , Christina N Kraus  2 , Krupa G Patel  3 , Anand K Ganesan  2 , Sergei A Grando  2
Affiliations

Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records

Candice Wang et al. Int J Dermatol. 2020 Feb.

Abstract

Background: Clinical trial data for dupilumab, a monoclonal antibody against the interleukin-4 receptor (IL-4Rα), have shown that it is safe and effective for the treatment of moderate to severe atopic dermatitis in patients whose disease is resistant to other therapies. However, little real-world experience with dupilumab use has been reported thus far. The aim of this retrospective study was to assess overall outcomes in adult patients with atopic dermatitis (AD) treated with dupilumab.

Methods: A retrospective review of electronic medical records was conducted for patients treated with dupilumab in the Department of Dermatology at the University of California, Irvine.

Results: We analyzed the medical records of 77 AD patients who received dupilumab according to standard dosing and had at least one documented follow-up visit. In 66 patients (86%), dupilumab improved clinical disease severity, with 23 patients (30%) experiencing complete clearance on dupilumab. Dupilumab was generally well-tolerated and caused no serious adverse events. The most common side effects included dry eyes, conjunctivitis, and keratitis. The most common reason for discontinuation of treatment was lack of substantial clinical improvement or progression of disease severity, followed by ophthalmologic side effects.

Conclusions: Overall, dupilumab was well-tolerated and resulted in clinical improvement in our patient population. These results provide additional important information on the safety and utility of dupilumab treatment for moderate to severe atopic dermatitis in the real-world clinical setting.

PubMed Disclaimer

References

    1. Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011; 242: 233-246.
    1. Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: Data from the 2003 national survey of children's health. J Invest Dermatol 2011; 131: 67-73.
    1. Chiesa Fuxench ZC, Block J, Boguniewicz M, et al. Atopic dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol 2019; 139: 583-590.
    1. Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456.
    1. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017; 139: S65-S76.

MeSH terms

LinkOut - more resources